Tandem Diabetes Care®, Inc., a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring (CGM) integration, today announced that it has received a Health Canada Medical Device License for the t:slim X2™ Insulin Pump.
The t:slim X2 Pump features Dexcom G5®Mobile CGM integration, making it the only CGM-integrated insulin pump approved in Canada for making daily diabetes treatment decisions without fingersticks.
“People with diabetes in Canada have been asking for our simple-to-use pump technology since the inception of Tandem and I am thrilled that we are now able to offer a fresh, new choice in insulin pump therapy,” said Kim Blickenstaff, president and CEO of Tandem Diabetes Care.
“This launch is especially important since insulin pump options in Canada have become increasingly limited in recent years, and this approval will allow us to bring the benefits of our technology to more people with diabetes,” she added.
The company plans to launch the t:slim X2 Insulin Pump on a province-by-province basis throughout the fourth quarter of 2018 pending the completion of pre-launch activities, including product registration with provincial health programs.
The simple-to-use t:slim X2 Insulin Pump includes advanced features like a large color touchscreen, rechargeable battery, USB connectivity and watertight construction (IPX7).
As the only insulin pump integrated with Dexcom G5 Mobile CGM, dynamic glucose data can be easily accessed and shared using a compatible mobile device. The t:slim X2 Pump is up to 38% smaller than other insulin pumps and holds up to 300 units of insulin.
Image: T:Slim X2 Insulin Pump with Basal-IQ Technology. Courtesy of Tandem Diabetes Care.
Tandem Diabetes Care Receives Health Canada Approval to Market t:slim X2 Insulin Pump. (2018. October 12). Tandem Diabetes Care. Retrieved from: https://www.businesswire.com/news/home/20181012005460/en